Medical Devices / Biotech - Diabetes Management & Non-invasive Diagnostics
Strategic Profile
Know Labs operates at the intersection of medical diagnostics and wearable technology, with a differentiated technology approach using electromagnetic spectroscopy to capture unique molecular signatures without invasive procedures. The company has recently undergone significant strategic transformation, with founder Ron Erickson continuing diagnostic research while new leadership pursues broader digital asset and blockchain initiatives following an acquisition by Greg Kidd's Goldeneye 1995, LLC in mid-2025.
Cyborg Score Rationale
Know Labs possesses innovative patented technology with clear clinical applications in a large diabetes management market. However, the company faces significant headwinds: pre-revenue status for its core product, substantial accumulated losses, complex FDA approval pathway, and recent dramatic strategic pivot away from core diagnostics focus raise uncertainty about long-term viability and management commitment to original mission.
Top Insights
Company rebranded to USBC, Inc. in August 2025 after acquisition, shifting strategic focus toward Bitcoin treasury and blockchain-based USBC token alongside diagnostics research
Core RFDS technology shows validation through multiple clinical trials and peer-reviewed research, including successful pH detection demonstrations
Pre-revenue stage for diagnostic products with FDA clearance required for glucose monitor launch; significant capital requirements and execution risk
Founder Ron Erickson transitioned to lead new diagnostic science division rather than executive leadership, signaling potential deprioritization of original medical mission
Named Competitors
Continuous Glucose Monitoring Systems — Established CGM providers with FDA-approved continuous glucose monitors for diabetes management
Non-invasive Glucose Monitoring Research — Various companies pursuing alternative non-invasive glucose monitoring technologies
Recent Developments
(August 2025) Strategic acquisition by Goldeneye 1995, LLC and name change to USBC, Inc.; new leadership including CEO Greg Kidd, implementation of Bitcoin treasury strategy
(February 2025) 1-for-40 reverse stock split; trading moved to OTC Pink Market under symbol KNWN due to NYSE American delisting proceedings
(March 2025) Participation in International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) to present non-invasive glucose monitor updates
Open the full interactive Know Labs, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.